{"entity":{"id":"antelope-surgical-solutions","kind":"company","name":"Antelope Surgical Solutions","aka":["Antelope Surgical"],"tldr":"Antelope Surgical Solutions makes small molecules that stick to prostate cancer cells and glow during surgery, so the surgeon can see where the tumour ends; the same molecule is designed to carry a radioactive label for scans or treatment.","summary":"Antelope Surgical Solutions, Inc. is a New York City clinical-stage radiopharmaceutical company founded in 2020, according to the company, developing multimodal small molecules for radioligand therapy, PET imaging and fluorescence-guided surgery. It states that it has built a GMP manufacturing facility with robotic high-throughput synthesis and received its first FDA IND clearance for its lead agent. AS1986NS is a fluorescent PSMA-targeting agent in a single-arm, blinded histopathology trial in men with prostate cancer (NCT06906471). Its first registered cancer trial, NCT06906471, was posted on ClinicalTrials.gov in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.antelopesurgical.com/"},{"label":"About","url":"https://www.antelopesurgical.com/about"},{"label":"ClinicalTrials.gov: fluorescent PSMA histopathology trial of AS1986NS (NCT06906471)","url":"https://clinicaltrials.gov/study/NCT06906471"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["radiopharma","surgery","imaging"],"technologies":["fluorescence-guided-surgery","psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06906471"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year, location and description from the company website, read on 29 October 2026. No financing round is recorded; the site's investor relations page was not read. The radioligand therapy and PET uses are the company's stated aims for its platform; the registered trial studies fluorescence-guided surgery only."],"hq":"New York, NY","country":"US","companyType":"radiopharma","website":"https://www.antelopesurgical.com/","founded":2020,"stage":"startup","investors":[],"funding":[]},"route":"/companies/antelope-surgical-solutions/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"trial":[{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/"}]}}